Revenue share from North America business fell to 52.4% in Q4 FY22 from 57% in Q4 FY21. Income from India business declined to 8.1% in Q4 FY22 when compared to 13.5% in Q4 FY21.
Meanwhile, revenue share from Latin America business increased to 11.9% in Q4 FY22 when compared to 8.9% in the same quarter last year while revenue share from Europe increased to 21.5% as against 14.5% in the corresponding quarter last year.
Profit before tax stood at Rs 150 crore in the fourth quarter, down by 2.51% from Rs 154 crore in the same period last year.
EBITDA stood at Rs 193 crore in Q4 FY22, falling 5% year on year while EBITDA margin slipped to 19% in Q4 FY22 from 25% in Q4 FY21.
On full year basis, the company reported a 25% declined in consolidated net profit to Rs 413 crore despite of a 16% rise in income from operations to Rs 3,765 crore in FY22 over FY21.
Commenting on the results, Dr Krishna Prasad Chigurupati, chairman & managing director of Granules India said, “FY22 has been a challenging year for the industry in the face of adverse external environment with headwinds around the availability and price for raw materials, solvents, catalysts, uncertainties arising out of Ukraine-Russia conflict as well as reemergence of Covid cases in China. The global supply chain and logistics continue to remain under duress. In face of these challenges, Granules has demonstrated great resilience and I am happy with the performance of the company. While we strive for continued improvement in our financial performance in the short term, we are working on long term strategy for making ourselves self-sustainable and overcome most of the challenges that we are facing now. We are now embarking on a new journey to reimagine our business model and transform Granules to an Innovative, science & technology driven organization, with responsible sustainable operations.”
Meanwhile, the board of directors of the company recommended final dividend of Re 0.75 per equity share for the financial year ended 31 March 2022.
Hyderabad-based Granules India is a vertically integrated fast growing Indian pharmaceutical company. It is present in the manufacturing of entire value chain - from active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs) and finished dosages (FDs).
Powered by Capital Market - Live News